Lotus Pharmaceutical Announces Acquisition of Product Rights for 'Matterhorn' in the Korean Market via Subsidiary Alvogen Korea
Lotus Pharmaceutical, a Taiwanese pharmaceutical company, announced that its subsidiary, Alvogen Korea, has acquired the intellectual property rights, marketing authorizations, and product technology related to the product 'Matterhorn' in the Korean market from OM PHARMA SA. The total transaction value is 69 million USD, aimed at optimizing the company's product portfolio.
📋 Article Processing Timeline
- 📰 Published: May 22, 2026 at 06:31
- 🔍 Collected: May 22, 2026 at 06:31 (0 min after Published)
- 🤖 AI Analyzed: May 22, 2026 at 06:40 (8 min after Collected)
Reporting Date: May 21, 2026
Company Code: 1795
Company Name: Lotus Pharmaceutical
The Board of Directors of Lotus Pharmaceutical has approved the purchase of intellectual property, marketing authorizations, and product technology related to the product 'Matterhorn' for the Korean market by its subsidiary, Alvogen Korea, from OM PHARMA SA.
1. Target: Intellectual property, marketing authorizations, and product technology related to the product 'Matterhorn' for sale in the Korean market held by OM PHARMA SA.
2. Total Transaction Value: 69 million USD.
3. Counterparty: OM PHARMA SA (Not a related party).
4. Purpose: Optimization of product portfolio.
5. Source of Funds: Internal capital and bank loans.
6. Decision Process: Decided after Board of Directors' approval, referencing a valuation report provided by an independent expert.
7. Others: The transaction amount was calculated based on the Taiwan Bank exchange rate of May 19, 2026 (1 USD = 31.65 TWD).
Company Code: 1795
Company Name: Lotus Pharmaceutical
The Board of Directors of Lotus Pharmaceutical has approved the purchase of intellectual property, marketing authorizations, and product technology related to the product 'Matterhorn' for the Korean market by its subsidiary, Alvogen Korea, from OM PHARMA SA.
1. Target: Intellectual property, marketing authorizations, and product technology related to the product 'Matterhorn' for sale in the Korean market held by OM PHARMA SA.
2. Total Transaction Value: 69 million USD.
3. Counterparty: OM PHARMA SA (Not a related party).
4. Purpose: Optimization of product portfolio.
5. Source of Funds: Internal capital and bank loans.
6. Decision Process: Decided after Board of Directors' approval, referencing a valuation report provided by an independent expert.
7. Others: The transaction amount was calculated based on the Taiwan Bank exchange rate of May 19, 2026 (1 USD = 31.65 TWD).
FAQ
What kind of company is Lotus Pharmaceutical?
A Taiwan-based pharmaceutical company with global operations. It focuses on growth through portfolio optimization and M&A.
What are the benefits of the acquired product?
By acquiring the rights for a product sold in the Korean market, the company expects to strengthen its local business foundation.
What is the strategic rationale behind the deal?
The goal is to optimize the product lineup and enhance long-term profitability and market competitiveness.